Previous 10 | Next 10 |
Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2019 Results Conference Call March 12, 2020 08:00 AM ET Company Participants Dr. Kimberly Lee - Head, IR and Corporate Strategy Lonnel Coats - President and CEO Alex Santini - EVP and Chief Commercial Officer Dr. Pablo Lapuerta - EVP and ...
Image source: The Motley Fool. Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) Q4 2019 Earnings Call Mar 12, 2020 , 8:00 a.m. ET Operator Continue reading
Lexicon Pharmaceuticals (NASDAQ: LXRX ): Q4 GAAP EPS of -$0.48 beats by $0.29 . Revenue of $8.73M (-48.9% Y/Y) misses by $1.53M . Shares -3.6% PM. Press Release More news on: Lexicon Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,
XERMELO ® (telotristat ethyl) 2019 U.S. Net Sales Reached $31.0 Million THE WOODLANDS, Texas, March 12, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months and full-year ended December 31, 2019 and ...
THE WOODLANDS, Texas, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today real-world data on XERMELO’s ® (telotristat ethyl) antiproliferative effects in patients with carcinoid syndrome that were presented at the American Socie...
THE WOODLANDS, Texas, Jan. 20, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that data from a poster highlighting XERMELO ® (telotristat ethyl) will be presented at the American Society for Clinical Oncology (ASCO) 2020 Symposium (January...
Investing in the best growth stocks can generate superior returns over the long term. On the other hand, growth stocks are also particularly volatile and risky. The key, like usually happens, is separating the fundamentally sound companies from the ones with mediocre fundamentals. The follow...
This has been a hard year for Lexicon Pharmaceuticals ( LXRX ), and I can understand why any good news would be welcome. Unfortunately, the three positive trial read-outs the company has offered in December don’t really change the value proposition and don’t really represent ...
Stealth BioTherapeutics (NASDAQ: MITO ) -56% after elamipretide flunks late-stage PMM study. More news on: Stealth BioTherapeutics Corp, Valeritas Holdings, Inc., Abeona Therapeutics Inc., Stocks on the move, Read more ...
A Phase 3 clinical trial, SOTA-EMPA , evaluating Lexicon Pharmaceuticals' (NASDAQ: LXRX ) Zynquista (sotagliflozin) in patients with type 2 diabetes (T2D) met the primary endpoint demonstrating its superiority versus placebo in lowering HbA1C levels at week 26. More news on: Lexicon Pha...
News, Short Squeeze, Breakout and More Instantly...
Lexicon Pharmaceuticals Inc. Company Name:
LXRX Stock Symbol:
NASDAQ Market:
Lexicon Pharmaceuticals Inc. Website:
THE WOODLANDS, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2024 financial results on Thursday, August 1, 2024 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00...
Launch Preparations Actively Underway; Launch Planned for Early 2025 Lexicon Seeks Approval for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease THE WOODLANDS, Texas, July 16, 20...
New analysis of the pivotal Phase 3 SOLOIST-WHF trial provides additional evidence of positive economic impact on hospitals participating in various alternative payment models (APM) Findings consistent with two peer-reviewed studies published in June 2024 THE WOODLANDS, Texa...